Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i> Mutant Pancreatic CancerCraig M. Goodwin, Channing J. Der, Andrew M. Waters et al.|Cancer Research|2022Cited by 160
Four drug-sensitive subunits are required for maximal effect of a voltage sensor–targeted KCNQ openerAlice Wang, Harley T. Kurata, Michael C. Yau et al.|The Journal of General Physiology|2018Cited by 22
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer.Mareen Lüthen, Sehrish Javaid, Irem Ozkan‐Dagliyan et al.|UNC Libraries|2024Cited by 12
Abstract LB-287: Combination therapies with CDK4/6 inhibitors to treat <i>KRAS-</i>mutant pancreatic cancerCraig M. Goodwin, Channing J. Der, Sehrish Javaid et al.|Cancer Research|2019Cited by 1
Figure S1 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic CancerCraig M. Goodwin, Channing J. Der, Andrew M. Waters et al.|Unknown|2023Cited by 0